title: Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis: a randomized placebo-controlled  trial.
abstract: BACKGROUND
  Little is known about the safety and effectiveness of early interventional treatment (EIT) with intranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebo-controlled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japanese cedar/cypress pollinosis (JCCP).
  
  
  METHODS
  A total of 50 JCCP patients received MFNS (200μg once daily: n = 25) or placebo (n = 25) starting on February 1, 2010. Treatments continued until the end of April. The primary endpoint was the comparison of the total nasal symptom score (TNSS) between the MFNS and placebo groups. The secondary endpoints included comparisons of QOL, daytime sleepiness, nasal ECP levels, and safety.
  
  
  RESULTS
  Continuous dispersion of Japanese cedar pollen began on February 22. Although the placebo group showed a significant worsening of symptoms after the start of the continuous dispersion, no worsening occurred in the MFNS group. A significant difference in the TNSS between the two groups was seen starting at 4 weeks after the treatment. Similar results were seen for QOL and sleepiness. Nasal ECP levels in March were significantly lower in the MFNS group. A total of 56% of the MFNS group progressed to a persistent allergic rhinitis state in accordance with the ARIA classification, as opposed to 84% of the placebo group. MFNS was well tolerated, and the plasma cortisol concentrations were similar between the two groups.
  
  
  CONCLUSIONS
  EIT with MFNS for JCCP is both safe and effective. This treatment can potentially lessen symptoms and help pollinosis patients remain in the intermittent state.
authors.affiliation: Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Makihara
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Okano
authors.forename: Tazuko
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Masayo
authors.initials: M
authors.lastname: Kimura
authors.forename: Takaya
authors.initials: T
authors.lastname: Higaki
authors.forename: Takenori
authors.initials: T
authors.lastname: Haruna
authors.forename: Yohei
authors.initials: Y
authors.lastname: Noda
authors.forename: Kengo
authors.initials: K
authors.lastname: Kanai
authors.forename: Shin
authors.initials: S
authors.lastname: Kariya
authors.forename: Kazunori
authors.initials: K
authors.lastname: Nishizaki
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D032485:Cryptomeria / Q000276:immunology; D029781:Cupressus / Q000276:immunology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D015508:Nasal Obstruction / Q000209:etiology / Q000517:prevention & control; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000009:adverse effects; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate